Systemic treatment for metastatic colorectal cancer in the era of precision medicine

Jaideep Sandhu; Viraj Lavingia; Marwan Fakih

doi:10.1002/jso.25421

Systemic treatment for metastatic colorectal cancer in the era of precision medicine

J Surg Oncol. 2019 Apr;119(5):564-582. doi: 10.1002/jso.25421. Epub 2019 Feb 25.

Authors

Jaideep Sandhu¹, Viraj Lavingia², Marwan Fakih³

Affiliations

¹ Department of Medical Oncology, City of Hope National Medical Center, Duarte, California.
² HCG Cancer Center, Ahmedabad, India.
³ Medical Oncology and Therapeutics Research, Briskin Center for Clinical Research, GI Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.

PMID: 30802315
DOI: 10.1002/jso.25421

Abstract

The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.

Keywords: biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / pathology*
ErbB Receptors / antagonists & inhibitors
Humans
Molecular Targeted Therapy
Mutation
Neoadjuvant Therapy
Precision Medicine*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Receptor, ErbB-2 / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
ERBB2 protein, human
ErbB Receptors
Receptor, ErbB-2
Proto-Oncogene Proteins B-raf